XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives o GARDEN ...

Beyond Air, Inc. (NASDAQ: XAIR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.67 per share a year ago.

Short interest in Beyond Air Inc (NASDAQ:XAIR) decreased during the last reporting period, falling from 966.68K to 852.16K. This put 1.33% of the company's publicly available shares short.

and Beyond Air (XAIR – Research Report) with bullish sentiments. Sensus Healthcare (SRTS) In a report released today, Ben Haynor from Lake Street maintained a Buy rating on Sensus Healthcare ...

GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...